IL262328B2 - Methods for administration and methods for treating cardiovascular diseases with resiniparatoxin - Google Patents

Methods for administration and methods for treating cardiovascular diseases with resiniparatoxin

Info

Publication number
IL262328B2
IL262328B2 IL262328A IL26232818A IL262328B2 IL 262328 B2 IL262328 B2 IL 262328B2 IL 262328 A IL262328 A IL 262328A IL 26232818 A IL26232818 A IL 26232818A IL 262328 B2 IL262328 B2 IL 262328B2
Authority
IL
Israel
Prior art keywords
rtx
trpv1
administration
receptor agonist
treatment
Prior art date
Application number
IL262328A
Other languages
English (en)
Hebrew (he)
Other versions
IL262328B (en
IL262328A (en
Inventor
Irving H Zucker
Hanjun Wang
Original Assignee
Univ Nebraska
Irving H Zucker
Hanjun Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska, Irving H Zucker, Hanjun Wang filed Critical Univ Nebraska
Publication of IL262328A publication Critical patent/IL262328A/en
Publication of IL262328B publication Critical patent/IL262328B/en
Publication of IL262328B2 publication Critical patent/IL262328B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL262328A 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniparatoxin IL262328B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322079P 2016-04-13 2016-04-13
PCT/US2017/027480 WO2017180907A1 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Publications (3)

Publication Number Publication Date
IL262328A IL262328A (en) 2018-11-29
IL262328B IL262328B (en) 2022-12-01
IL262328B2 true IL262328B2 (en) 2023-04-01

Family

ID=60039929

Family Applications (2)

Application Number Title Priority Date Filing Date
IL262328A IL262328B2 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniparatoxin
IL298314A IL298314B2 (en) 2016-04-13 2017-04-13 Methods of administration and methods of treating cardiovascular diseases with resiniparatoxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL298314A IL298314B2 (en) 2016-04-13 2017-04-13 Methods of administration and methods of treating cardiovascular diseases with resiniparatoxin

Country Status (8)

Country Link
US (3) US20170296506A1 (enExample)
EP (1) EP3442523A4 (enExample)
JP (3) JP6980694B2 (enExample)
KR (2) KR102395342B1 (enExample)
CN (2) CN120114438A (enExample)
AU (1) AU2017248665B2 (enExample)
IL (2) IL262328B2 (enExample)
WO (1) WO2017180907A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490745A (zh) 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
WO2020154261A1 (en) 2019-01-22 2020-07-30 Sorrento Therapeutics, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin
CN116744867A (zh) * 2020-08-11 2023-09-12 索伦托药业有限公司 通过神经消融治疗肺部炎性疾病
WO2022245791A1 (en) * 2021-05-18 2022-11-24 Sorrento Therapeutics, Inc. Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829028B2 (en) * 2002-05-16 2014-09-09 Serodus As 5-HT4 receptor antagonists for the treatment of heart failure
US20150080460A1 (en) * 2013-09-18 2015-03-19 Board Of Regents Of The University Of Nebraska Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607219A1 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity
SI1976521T1 (sl) * 2006-01-25 2015-06-30 Insys Therapeutics, Inc. Podjezično fentanilno pršilo
EP2007376B1 (en) * 2006-03-13 2013-05-08 Hadasit Medical Research Services And Development Ltd. Therapeutic uses of cannabidiol compounds
CN101522181A (zh) * 2006-10-04 2009-09-02 纽若科伊公司 诱导低体温药物在治疗局部缺血的应用
CN101951937A (zh) * 2007-12-21 2011-01-19 赫尔辛医疗股份公司 使用伊帕瑞林刺激胃肠系统动力的方法
US8846324B2 (en) * 2010-10-06 2014-09-30 Celltrend Gmbh In vitro method for diagnosing or predicting hypertension and/or early-stage cardiovascular end-organ damage by determining the concentration of soluble prorenin receptor
MX368865B (es) * 2013-09-17 2019-08-02 Vectus Biosystems Ltd Composiciones para el tratamiento de hipertension y/o fibrosis.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829028B2 (en) * 2002-05-16 2014-09-09 Serodus As 5-HT4 receptor antagonists for the treatment of heart failure
US20150080460A1 (en) * 2013-09-18 2015-03-19 Board Of Regents Of The University Of Nebraska Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOUIS S. PREMKUMAR, TARGETING TRPV1 AS AN ALTERNATIVE APPROACH TO NARCOTIC ANALGESICS TO TREAT CHRONIC PAIN CONDITIONS, 30 September 2010 (2010-09-30) *
WANG, H ET AL.,, THORACIC EPIDURAL ADMINISTRATION OF RESINIFERATOXIN IMPROVES CARDIAC AND AUTONOMIC DYSFUNCTION IN POST-MI RATS, 31 December 2015 (2015-12-31) *

Also Published As

Publication number Publication date
IL298314B1 (en) 2024-12-01
JP6980694B2 (ja) 2021-12-15
JP7341203B2 (ja) 2023-09-08
CA3020815A1 (en) 2017-10-19
IL262328B (en) 2022-12-01
US20250082605A1 (en) 2025-03-13
EP3442523A1 (en) 2019-02-20
IL298314B2 (en) 2025-04-01
KR20190029511A (ko) 2019-03-20
KR102508022B1 (ko) 2023-03-10
IL298314A (en) 2023-01-01
KR102395342B1 (ko) 2022-05-10
IL262328A (en) 2018-11-29
AU2017248665A1 (en) 2018-11-08
JP2022001608A (ja) 2022-01-06
US20220000837A1 (en) 2022-01-06
CN109562096A (zh) 2019-04-02
EP3442523A4 (en) 2019-12-04
KR20220062667A (ko) 2022-05-17
JP2023155365A (ja) 2023-10-20
CN120114438A (zh) 2025-06-10
US20170296506A1 (en) 2017-10-19
WO2017180907A1 (en) 2017-10-19
JP2019511536A (ja) 2019-04-25
AU2017248665B2 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
US20250082605A1 (en) Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin
Fiorelli et al. Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication
Russo et al. 10-kHz high-frequency SCS therapy: a clinical summary
Krutsch et al. A case report of subcutaneous peripheral nerve stimulation for the treatment of axial back pain associated with postlaminectomy syndrome
Jordan et al. Electrical carotid sinus stimulation in treatment resistant arterial hypertension
Schumacher et al. Treatment of venous malformations: first experience with a new sclerosing agent–a multicenter study
Brull et al. The corner pocket revisited
CA3020815C (en) Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
Fischer et al. Complications associated with locoregional anesthesia
Schlaich et al. New therapeutic approaches to resistant hypertension
Madhavan et al. Renal nerve stimulation for the treatment of neurocardiogenic syncope
Singh et al. Late-breaking science from the Heart Rhythm Society 2019
Price Comment on" Minimum Effective Volume of Local Anesthetic for Shoulder Analgesia by Ultrasound-Guided Block at Root C7 With Assessment of Pulmonary Function"
Lucas et al. Extracorporeal shock wave therapy and percutaneous nephrolithotripsy
Bhatt et al. Erector Spinae Plane (ESP) Block Decreases Narcotic Requirement in Patients Undergoing Subcutaneous ICD Placement Under Sedation
IL324230A (en) Composition for the treatment of refractory painful intervertebral disc related disorders and method for delivery thereof to treat thereto
Choudhary et al. Anaesthetic management of intracranial aneurysm in patient with coarctation of aorta
Maciąg et al. One step behind to step ahead–femoral approach to stabilize and to extract functional pacing lead to regain venous access
Renes et al. Reply to Dr. Price
Weinberg Reply to Dr. Heller
Hong The effects of stellate ganglion block on intraoperative hemodynamics and postoperative side effects in laparoscopic day-case surgery
Markowitz Systemic toxicity treated with soya oil emulsion: case report
Shalaby Ahmed Adel Abd El Fattah El beleehy